Head to Head Review: Sientra (NASDAQ:SIEN) vs. Demant A/S (OTCMKTS:WILLF)

Sientra (NASDAQ:SIEN) and Demant A/S (OTCMKTS:WILLF) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Valuation & Earnings

This table compares Sientra and Demant A/S’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sientra	$90.55 million	0.00	-$73.31 million	($5.57)	N/A
Demant A/S	N/A	N/A	N/A	$23.08	2.23

Demant A/S has lower revenue, but higher earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than Demant A/S, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

15.4% of Sientra shares are owned by institutional investors. Comparatively, 13.6% of Demant A/S shares are owned by institutional investors. 1.5% of Sientra shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Sientra and Demant A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sientra	0	1	1	0	2.50
Demant A/S	0	0	0	0	N/A

Sientra presently has a consensus target price of $7.50, indicating a potential upside of ∞. Given Sientra’s higher probable upside, research analysts plainly believe Sientra is more favorable than Demant A/S.

Profitability

This table compares Sientra and Demant A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sientra	-65.93%	N/A	-40.45%
Demant A/S	N/A	N/A	N/A

Summary

Sientra beats Demant A/S on 5 of the 9 factors compared between the two stocks.

About Sientra

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides fat transfer systems; body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists, and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Irvine, California. On February 12, 2024, Sientra, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

About Demant A/S

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services. The Communications segment provides headsets and solutions for the professional call centers, office markets, and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.